Soluble Interleukin-2 Receptor Secretion Defect in Vitro in HLA-B8, DR3 Positive Subjects

References

• Dausset J, Contu L. The MHC and immune response in man. Immunology 80. Progress in Immunology IV, M Fougerau, J Dausset. Academic Press, London 1980; 513–529
   Google Scholar
• Moller G. HLA and disease susceptibility. Immunological Reviews 1983; 70: 1–218
   PubMedGoogle Scholar
• HLA in medicine. M J Crumpton British Med Bull 431–245
   Google Scholar
• Caruso C, Palmeri P, Ferraro A, Modica M A. Effect of HLA-DR phenotype on natural allohemoag-glutinins versus A and B erythrocyte antigens. IRCS Med Sci 1985; 13: 354–355
   Google Scholar
• Fraser P A, Schur P H. Hypoimmunoglobulinemia D: frequency, family studies and association with HLA. Clin Immunol Immunopathol 1981; 19: 67–74
   PubMedGoogle Scholar
• Cryan E M, Stevens F M, Skehill R, Bourke M, Grimes H, McCarthy C F. Immunoglobulins in healthy controls: HLA-B8 and sex differences. Tissue Antigens 1985; 26: 254–258
   PubMedGoogle Scholar
• Feehally J, Brenchley P E C, Coupes B M, Mallick N P, Morns D M, Short C D. Impaired IgG response to tetanus toxoid in human membranous nephropaty: association with HLA-DR3. Clin Exp Immunol 1986; 63: 376–384
   PubMedGoogle Scholar
• McCombs C C, Michalski J P. Lymphocyte abnormality associated with HLA-B8 in healthy young adults. J Exp Med 1982; 156: 936–941
   PubMed Web of Science ®Google Scholar
• McCombs C C, Michalski J P, deShazo R, Bozelka B, Lane J T L. lmmune abnormalities associated with HLA-B8: Lymphocyte subsets and functional correlates. Clin Immunol Immunopathol 1986; 39: 112–120
   PubMedGoogle Scholar
• Caruso C, Lio D, Palmeri P, Cillari E. HLA-DR phenotypes and blood levels of T cell subsets. Tissue Antigens 1984; 24: 320–322
   PubMedGoogle Scholar
• Caruso C, Cillari E, Palmeri P, Lio D, Salerno A. OKT4+ and OKT8+ cell subset values and HLA-DR phenotypes. J Clin Lab Immunol 1985; 16: 91–92
   PubMedGoogle Scholar
• Caruso C, Modica M A, Lio D, Cillari E. HLA-DR-linked genes are involved in the control of T lymphocyte blood levels. Clin Immunol Immunopathol 1987; 44: 160–166
   PubMedGoogle Scholar
• Lawley T J, Hall R P, Fauci A S, Katz S I, Hamburger M I, Frank M M. Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype. New England J Med 1981; 304: 185–192
   PubMed Web of Science ®Google Scholar
• Amer A, Singh G, Darke C, Dolby A E. Impaired lymphocyte responsiveness to phytohaemagglutinin associated with the possession of HLA-B8/DR3. Tissue Antigens 1986; 28: 193–198
   PubMedGoogle Scholar
• Caruso C, Salerno A. HLA-B8, DR3 phenotype and the in vitro response to phytochemoagglutinin. Tenth International Histocompatibility Conference (abstract). 1987; 546
   Google Scholar
• Caruso C, Zambito A M, Modica M A. Nei soggetti normali positivi per il fenotipo HLA-BS.DR3, si riscontrano alterazioni di alcune funzioni dei T linfociti che si osservano anche in corso di malattie autoimmuni. Atti XIX Congr Soc It Patol 1988; 343–346
   Google Scholar
• Caruso C, Bellina L. B8,DR3 antigens and production of human leucocyte migration inhibitory factor (LIF) by mononuclear cells stimulated with Concanavalin A (Con A). Tissue Antigens 1983; 22: 167–169
   PubMedGoogle Scholar
• Caruso C, Modica M A, Salerno A. Reduced rate of interleukin 2 (IL-2) production in vitro in the B8, DR3 phenotypes. Proc. 18 Congress of Italian Society of Pathology, L Frati, M Piccoli, A Santoni, Rome 1986; 270–272
   Google Scholar
• Davey F R, Kurec A S, Doch N L, Hubbell C, Falen S W. Association of HLA-DR antigens with the autologous mixed lymphocyte reaction. Tissue Antigens 1984; 24: 98–106
   PubMedGoogle Scholar
• Ambinder J M, Chiorazzi N, Gibofsky A, Fotino M, Kunkel H G. Special characteristics of cellular immune function in normal individuals of the HLA-DR3 type. Clin Immunol Immunopathol 1982; 23: 269–274
   PubMedGoogle Scholar
• Legrand L, Rivat-Perran L, Huttin C, Dausset J. HLA-and Gm-linked genes affecting the degradation rate of antigens (sheep red blood cells) endocytized by macrophages. Human Immonol 1982; 4: 1–13
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Tarn A C, Gale E A M. HLA-DR3 and activated lymphocytes: significance in autoim-munity. The Lancet 1985; i: 954–955
   Google Scholar
• Modica M A, Freddi S, Caruso C. Blood IgA, IgM and IgE levels are influenced by sex and HLA phenotype. Exp Clin Immunogenetics 1989; 6: 251–257
   PubMedGoogle Scholar
• Hashimoto S, McCombs C C, Michalski J P. Mechanism of a lymphocyte abnormality associated with HLA-B8, DR3 in clinically healthy individuals. Clin Exp Immunol 1989; 76: 317–323
   PubMedGoogle Scholar
• Modica M A, Cammarata G, Caruso C. HLA-B8,DR3 phenotype and lymphocyte responses to phytohaemoagglutinin. J Immunogenetics 1990; 17, in press
   PubMedGoogle Scholar
• Caruso C, Candore G, Modica M A. Nonresponse to Hepatitis B vaccine. N Engl J Med 1990; 332: 550–551, letter
   Google Scholar
• Yu D T Y, Winchester R J, Fu S M, Gibofsky A, Ko H S, Kunkel H G. Peripheral blood Ia-positive T cells. J Exp Med 1980; 151: 91–100
   PubMed Web of Science ®Google Scholar
• Alviggi L, Hoskins P J, Pyke D A, Johnston C, Tee D E H, Leslie R D G, Vergani D. Pathogenesis of insulin-dependent diabetes: a role for activated T lymphocytes. Lancet 1984; 1: 4–6
   PubMedGoogle Scholar
• Bellamy A S, Calder V L, Feldmann M, Davison A N. The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes. Clin Exp Immunol 1985; 61: 248–256
   PubMed Web of Science ®Google Scholar
• Hafler D A, Fox D A, Manning M E, Schlossman S F, Reinherz E L, Weiner H L. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985; 312: 1405–1411
   PubMed Web of Science ®Google Scholar
• Kennedy R, Di Mario U, Pozzilli P, Guy K, Leonardi M, Sensi M, Andreani D. Activated T cells in Graves' disease before treatment. Clin Exp Immunol 1985; 59: 377–382
   PubMedGoogle Scholar
• Scudeletti M, Indiveri F, Pierri I, Picciotto A, Ferrone S. T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions. Cellular Immunol 1986; 102: 227–233
   PubMedGoogle Scholar
• Giordano C, Panto F, Caruso C, Modica M A, Amato M P, Galluzzo A. Markers of stimulated T lymphocyte activation at the onset of Type I (insulin-dependent) diabetes. Med Sci Res 1988; 16: 423–424
   Google Scholar
• Raziuddin S, Danial H B, Kelley M. OKT4 + T cell abnormality in patients with active systemic lupus erythematosus: HLA-DR antigen expression. Clin Immunol Immunopathol 1988; 48: 42–49
   PubMedGoogle Scholar
• Roncarolo M G, Zoppo M, Bacchetta R, Gabiano C, Sacchetti C, Cerutti F, Too P A. Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. Clin Immunol Immunopathol 1988; 49: 53–62
   PubMedGoogle Scholar
• Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocyte from patients systemic lupus erythematosus. J Clin Invest 1982; 69: 1388–1393
   PubMed Web of Science ®Google Scholar
• Gupta S. Autologous mixed lymphocyte reaction in health and disease states in man. Vox Sang 1983; 44: 265–270
   PubMed Web of Science ®Google Scholar
• Dinarello C A, Mier J W. Current concept lymphokines. New England J Med 1987; 317: 940–945
   PubMed Web of Science ®Google Scholar
• Giordano C, Caruso C, Panto F, Modica M A, Zambito A M, Amato M P, Galluzzo A. Dissociated production of interleukin-2 and immune gamma-interferon by phytohemoagglutinin stimulated peripheral mononuclear cells in type I (insulin-dipendent) diabetes. J Clin Lab Immunol 1988; 27: 73–76
   PubMedGoogle Scholar
• Giordano C, Panto F, Caruso C, Modica M A, Zambito A M, Sapienza N, Amato M P, Galluzzo A. Interleukin-2 and soluble interleukin 2–receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes 1989; 38: 310–315
   PubMedGoogle Scholar
• Rasanen L, Hyoty H, Lehto M, Kallioniemi O P, Antonen J, Huupponen T, Karjalainen J, Leinikki P. Defective autologous mixed leukocyte reaction in newly diagnosed type I diabetes mellitus. Clin Exp Immunol 1988; 71: 470–474
   PubMedGoogle Scholar
• Linker-Israeli M, Bakke A C, Kitridou R C, Gendler S, Gillis S, Horwitz D A. Defective production of interleukin I and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 2651–2655
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Nakamura T, Russell I J, Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopaathol 1984; 31: 109–117
   PubMedGoogle Scholar
• Fox R I, Theofilopoulos A N, Altman A. Production of interleukin 2 (IL2) by salivary gland lymphocytes in Sjogren's sindrome. Detection of reactive cells by using antibody directed to synthetic peptides of IL2. J Immunol 1985; 135: 3109–3115
   PubMed Web of Science ®Google Scholar
• Greene W C, Leonard W J. The human interleukin-2 receptor. Annu Rev Immunol 1986; 4: 69–95
   PubMed Web of Science ®Google Scholar
• Moller G. IL-2: Receptors and Genes. Immunological Reviews. 1986; 92: 1–156
   PubMedGoogle Scholar
• Malkovski M, Sondel P M, Strober W, Dalgleish A G. The interleukins in acquired disease. Clin Exp Immunol 1988; 74: 151–161
   PubMedGoogle Scholar
• Pizzolo G. The soluble interleukin-2 receptor as a new biological marker in diseases. Immunol Clin 1988; 7: 13–21
   Google Scholar
• Rubin L A, Kurman C, Fritz M E, Biddison W E, Boutin B, Yarchoan R, Nelson D L. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172–3177
   PubMed Web of Science ®Google Scholar
• Rubin L A, Jay G, Nelson D L. The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 1986; 137: 3841–3844
   PubMed Web of Science ®Google Scholar
• Giordano C, Galluzzo A, Marco A, Panto F, Amato M P, Caruso C, Bompiani G D. Increased soluble interleukin-2 receptor levels in the sera of type I diabetic patients. Diabetes Res 1988; 8: 135–138
   PubMedGoogle Scholar
• Manoussakis M N, Papadopoulos G K, Drosos A A, Moutsopoulos H M. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989; 50: 321–332
   PubMedGoogle Scholar
• Caruso C, Oliva L, Palmeri P, Cottone M. B-cell alloantigens in Sicilian patients with Crohn's disease. Tissue Antigens 1983; 21: 170–172
   PubMedGoogle Scholar
• Caruso C, Palmeri P, Oliva L, Orlando A, Cottone M. HLA antigens in ulcerative colitis: a study in the Sicilian population. Tissue Antigens 1985; 25: 47–49
   PubMedGoogle Scholar
• Caruso C, Cammarata G, Sireci G, Modica M A. HLA-CW4 association with acute lymphoblastic leukaemia in Sicilian patients. Vox Sanguinis 1988; 54: 57–58
   PubMedGoogle Scholar
• Gallina G, Cumbo V, Messina P, Caruso C. HLA-A, B, C, DR, MT and MB antigens in recurrent aphtous stomatis. Oral Surgery, Oral Medicine. Oral Pathology 1985; 59: 364–370
   Google Scholar
• Gallina G, Cumbo V, Messina P, Modica M A, Caruso C. MHC-linked genetic factor (HLA-B35) influencing recurrent circumoral herpetic lesions. Disease Markers 1987; 5: 191–197
   PubMedGoogle Scholar
• Statistical Methods in Medical Research, P Armitage. Blackwell, London 1971
   Google Scholar
• Amaro D. J. HLA polymorphism and immunogenetics. thesis, Universitv of Leiden. 1978
   Google Scholar
• Candore G, Di Giulio C, Caruso C. Decreased frequency of mitogen-responsive T lymphocyte precursors in HLA-BI, DR3–positive individuals. Med Sci Res 1989; 17: 735–736
   Google Scholar